First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer
Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.
Related Articles
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.
Retifanlimab Emerges as Potential New SOC in Advanced SCAC
Sheela Rao, MBBS, MD, FRCP, discusses data from the phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab plus chemotherapy vs chemotherapy in advanced SCAC.
17th Annual Hematologic Malignancies Demystified 2025 | Virtual
Register now for HMD 2025 and explore groundbreaking advancements in hematology. Stay informed with the latest innovations shaping the future of hematology research presented at…
Nivolumab Plus Chemo Improves OS in Chinese Patients With Advanced Gastric/GEJ Cancer
The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and…
FDA Releases Draft Guidance on Tissue Biopsies in Clinical Trials
The FDA has issued a draft guidance offering recommendations regarding tissue biopsies in clinical trials for pediatric and adult patients.
Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer
Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
An integrated intervention had the greatest impact in a randomized trial
Trastuzumab/Pertuzumab/Chemo Does Not Confer Response Advantage in Gastric/GEJ Cancer
Trastuzumab/pertuzumab/chemotherapy was associated with higher rates of toxicity and no mpRR improvement vs chemotherapy alone in HER2+ gastric cancer.
ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy
About the survey This survey aims to evaluate oncologists’ attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in…
